HCC - HEPATOCELLULAR CARCINOMA

This early-stage study tests a new drug called TGI-5, alone or with another drug (nivolumab), in people with advanced solid tumors like colorectal, liver, melanoma, and lung cancer. The main goals are to check safety and find the right dose. About 194 adults will take part. This …

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety. About 10 participants will receive one of two dose lev…

This study tests a new drug called AST-3424 in people with a specific type of advanced liver cancer that has high levels of a protein called AKR1C3 and has stopped responding to standard immunotherapy. The goal is to see if AST-3424 helps people live longer compared to another dr…

This study tests a new treatment called INT001 for adults with liver cancer who cannot have surgery. Doctors inject the drug directly into the tumor using a needle guided by imaging. The goal is to see if it can completely destroy the tumor and to check for any side effects. Part…

This study tests a new treatment for people with advanced liver cancer that cannot be removed by surgery. It combines precise proton radiation with two immunotherapy drugs (tremelimumab and durvalumab) to boost the immune system's attack on the tumor. About 45 participants will r…

This study tests a new combination of drugs and a procedure for people with liver cancer that cannot be cured by surgery. About 40 participants will receive an experimental pill (CVM-1118), an immunotherapy drug (sintilimab), and a targeted treatment called TACE that blocks the t…

This study compares two ways of giving the drugs bevacizumab and atezolizumab for advanced liver cancer that occurs with fatty liver disease. One group gets the drugs one after the other (sequential), the other gets them together (concurrent). The goal is to see which approach wo…

This pilot study tests a new approach for people with liver cancer that cannot be removed by surgery. The goal is to see if combining immunotherapy with targeted radiation can shrink the tumor enough to allow surgery. About 30 participants will be enrolled at the University of Ho…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the tumors. About 350 participants will take part in this early-phase trial.

This study tests whether adding interventional procedures (like targeted chemo or radiation) to standard immunotherapy and targeted therapy can better control advanced liver cancer. About 300 adults with advanced liver cancer will be split into two groups: one gets only drug ther…

This study tests a combination of four drugs (ipilimumab, sintilimab, bevacizumab biosimilar, and chemotherapy into the liver artery) to shrink advanced liver cancer that cannot be surgically removed. The goal is to make enough tumors shrink so that patients can then have surgery…

This study tests a special PET/CT scan that uses a radioactive tracer to see if it can find liver cancer (HCC) more accurately than standard scans. About 40 adults with newly diagnosed or suspected returning liver cancer will take part. The goal is to improve how doctors detect a…

This study compares a newer, more detailed CT scan (spectral CT) with a standard CT scan to see which one better finds any leftover cancer after a liver tumor treatment called TACE. About 250 adults with liver cancer will get both scans after their TACE procedure. The goal is to …

This study looks at 15 adults with liver cancer who are getting a precise type of radiation called SBRT. Researchers will take blood samples before, during, and after treatment to measure tiny bits of tumor DNA floating in the blood. The goal is to see if changes in this DNA can …